Synergy Between Two Mechanisms of Action Contributes to Species Differences in the Liver Safety Profile for PF-04895162

Authors: Lakhani VV, Generaux GT, Yang Y, Nadanaciva S, Qiu L, Riccardi K, Di L, Howell BA, Siler SQ, Watkins PB, Barton HA, Aleo MD, Shoda LKM
Conference: AAPS
Keywords: drug induced liver injury (DILI), in vivo, liver safety, pharmacology
Software: DILIsym®
Division: DILIsym Services

Purpose

The Purpose is to better understand the mechanisms underlying the apparent species differences, between rat and human, when evaluating the liver safety of compound PF-04895162. This case study of PF-04895162 fits into the broader, pharmacology goal of improving the detection of potential liver liabilities prior to the introduction of compounds to the clinic.

By Vinal V. Lakhani1, Grant Generaux1, Yuching Yang, Sashi Nadanaciva, Luping Qiu, Keith Riccardi, Li Di, Brett A. Howell, Scott Q. Siler, Paul B. Watkins, Hugh A. Barton, Michael D. Aleo, Lisl K. M. Shoda

2019 AAPS Annual Meeting PharmSci 360, November 3-6, 2019, San Antonio, Texas